:::
Chih-Ho Lai Ph.D.

Chih-Ho Lai Ph.D.

JobTitle： Professor

CurrentJob： Graduate Institute of Biomedical Sciences / Division of Microbiology and Immunology

E-mail： chlai@mail.cgu.edu.tw

Phone： 03-2118800 #5116

Education： National Tsing Hua University, Taiwan

Expertise： Infection and Immunity

Employment Records

2016 Research Fellow, Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital
2015 Professor, Department of Microbiology and Immunology, Chang Gung University
2015   Professor, Graduate Institute of Biomedical Sciences, Chang Gung University
2013 Professor, Department of Microbiology and Immunology, China Medical University
2011 Assistant Professor, Department of Urology, The University of Texas Southwestern Medical Center
2006 Assistant Professor, Department of Microbiology and Immunology, China Medical University
2005 Post-doctoral fellow, Infectious Disease Control and International Medicine, Niigata University, Japan

Education

2000-2005       Ph.D., Department of Life Science, National Tsing Hua University

1994-1996       M.S., Graduate Institute of Microbiology and Immunology, National Defense Medical Center

1990-1994       B.S., Department of Medical Technology, China Medical College

Research Interests

Our research focuses on elucidating the molecular mechanisms by which microbial virulence factors influence host immune defense responses. We have investigated bacterial toxins associated with pathogenesis, particularly from Helicobacter pylori, Campylobacter jejuni, Clostridioides difficile, and Clostridium innocuum. Recently, our laboratory has broadened its research to explore the impact of environmental pollutants, including PM2.5, microplastics, and carbon black, on microbial infections, host immune defenses, and microbiota composition. Through an interdisciplinary approach, we aim to uncover novel insights into the complex interactions between environmental factors, microbial pathogens, and the immune system, ultimately contributing to the development of innovative strategies for disease prevention and treatment.


[感染免疫實驗室]
Laboratory of Infection and Immunity

Publications

  • Yeh JA, Huang HK, Chou AL, Lin HJ, Feng CL, Kuo CJ, Lai CH*. Helicobacter pylori eradication with high-dose proton pump inhibitor-amoxicillin dual therapy: A systematic review and meta-analysis. Int J Antimicrob Agents. 2024;63(6):107159.
  • Ma J†, Chiu YF†, Kao CC, Chuang CN, Chen CY, Lai CH†, Kuo ML*. Fine particulate matter manipulates immune response to exacerbate microbial pathogenesis in the respiratory tract. Eur Respir Rev. 2024 Sep 4;33(173):230259. (†equal contribution)
  • Chang YF, Huang YP, Chou CH, Ho MW, Lin HJ, Chen CY, Wu HY, Lai YR, Lee YH, Chiu CH, Lai CH*. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin. J Microbiol Immunol Infect. 2024:S1684-1182(24)00118-X. 
  • Ho SM†, Tsai WH†, Lai CH†, Chiang MH, Lee WP, Wu HY, Bai PY, Wu T, Wu CL*. Probiotic Lactobacillus spp. improves Drosophila memory by increasing lactate dehydrogenase levels in the brain mushroom body neurons. Gut Microbes. 2024;16(1):2316533. (†equal contribution)
  • Huang HL, Lai CH, Tsai WH, Chen KW, Peng SL, Lin JH, Lin YH. Nanoparticle-enhanced postbiotics: Revolutionizing cancer therapy through effective delivery. Life Sci. 2024;337:122379.
  • Kuo CJ, Bui NN, Ke JN, Lin CY, Lin WR, Chang ML, Wu HY, Huang MZ, Chiu CH, Chiu CT, Lai CH*. Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan. Int J Infect Dis. 2023;138:25-28. 
  • Wu HY, Kuo CJ, Chou CH, Ho MW, Chen CL, Hsu TS, Chen YC, Chiang-Ni C, Chen YM, Chiu CH, Lai CH*. Clostridium innocuum, an emerging pathogen that induces lipid raft-mediated cytotoxicity. Virulence. 2023;14(1):2265048.
  • Bui NN, Li CY, Wang LY, Chen YA, Kao WH, Chou LF, Hsieh JT, Lin H, Lai CH*. Clostridium scindens metabolites trigger prostate cancer progression through androgen receptor signaling. J Microbiol Immunol Infect. 2023;56(2):246-256.
  • Kuo CJ, Ke JN, Kuo T, Lin CY, Hsieh SY, Chiu YF, Wu HY, Huang MZ, Bui NN, Chiu CH, Chiu CT, Lai CH*. Multiple amino acid substitutions in penicillin-binding protein-1A confer amoxicillin resistance in refractory Helicobacter pylori infection. J Microbiol Immunol Infect. 2023;56(1):40-47.
  • Lai CH*, Lin TL, Huang MZ, Li SW, Wu HY, Chiu YF, Yang CY, Chiu CH, Lai HC*. Gut commensal P. goldsteinii MTS01 alters gut microbiota composition and reduces cholesterol to mitigate Helicobacter pylori-induced pathogenesis. Front Immunol. 2022;13 (916848):1-13.
  • Chou LF, Chen TW, Yang HY, Tian YC, Chang MY, Hung CC, Lai CH, Hsu SH, Tsai CY, Ko YC, Lian JH, Yang CW. Implication of the IL-10-expression signature in the pathogenicity of Leptospira-infected macrophages. Microbiol Spectr. 2022;10(3):e0259521.
  • Lo UG, Chen YA, Cen J, Deng S, Luo J, Zhau H, Ho L, Lai CH, Mu P, Chung LWK, Hsieh JT*. The driver role of JAK-STAT signaling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer. Clin Transl Med. 2022;12(8):e978.
  • Chiang MH, Ho SM, Wu HY, Lin YC, Tsai WH, Wu T, Lai CH*, Wu CL*. Drosophila model for studying gut microbiota in behaviors and neurodegenerative diseases. Biomedicines. 2022;10(3):596.
  • Lee CF, Chen YA, Hernandez E, Pong RC, Ma S, Hofstad M, Kapur P, Zhau H, Chung LW, Lai CH, Lin H, Lee MS, Raj GV, Hsieh JT*. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC. Clin Transl Med. 2022;12(2):e695.
  • Hsu CY, Yeh JY, Chen CY, Wu HY, Chiang MH, Wu CL, Lin HJ, Chiu CH, Lai CH*. Helicobacter pylori cholesterol-α-glucosyltransferase manipulates cholesterol for bacterial adherence to gastric epithelial cells. Virulence. 2021;12(1): 2341-2351.